A Study to Assess Impulsivity and its Association with Post-Treatment Relapse in Subjects with Substance Use Disorders

Overview

About this study

Impulsivity is a major component of addictive behavior contributing to the initiation and perpetuation of Substance Use Disorders (SUDs). The purpose of this study is to investigate the correlation of self-reported measures of impulsivity, neurocognitive task measures of impulsivity,  with craving intensity, the correlation of neurocognitive task measures of impulsivity, and the association between impulsivity measures and sequence variability in the A2AR gene.  

 


 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Primary diagnosis of any SUD as per DSM 5 criteria
  • Able to understand English
  • Consenting to be included in the study and for post-treatment follow up data collection by the IAP staff

Exclusion Criteria: 

  • Unable or unwilling to sign informed consent
  • Psychiatrically or medically unstable as determined by study personnel Presence of moderate to severe alcohol withdrawal (Clinical Institute Withdrawal Assessment for Alcohol, CIWA score > 5) 
  •  Taking medication for alcohol withdrawal that could affect informed consent

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Victor Karpyak, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20304390

Mayo Clinic Footer